挂牌底价10.23亿元，上海医药拟清仓中美施贵宝

Core Viewpoint - Shanghai Pharmaceuticals plans to transfer its 30% stake in China Bristol-Myers Squibb through a public listing, with a minimum transfer price of 1.023 billion yuan [1] Group 1: Stake Transfer Details - The current ownership of China Bristol-Myers Squibb consists of three parties: 60% by Bristol-Myers Squibb (China) Investment Co., Ltd., 30% by Shanghai Pharmaceuticals, and 10% by China National Pharmaceutical Group Asset Management Co., Ltd. [1] - If the transfer is successful, Shanghai Pharmaceuticals will no longer hold any stake in China Bristol-Myers Squibb [1] - Bristol-Myers Squibb is also planning to transfer its 60% stake, with potential buyers expected to submit confirmation bids by June 2025, valuing the entire company at 480 million USD [1] Group 2: Financial Performance of China Bristol-Myers Squibb - The company has experienced a decline in performance due to centralized procurement and competition, with revenues of 1.795 billion yuan and a net profit of 248 million yuan in 2024 [2] - For the first three quarters of 2025, revenues dropped to 1.096 billion yuan and net profit to approximately 87.12 million yuan, significantly lower than the peak revenues of 4.724 billion yuan and net profits of 622 million yuan in 2016 [2] Group 3: Shanghai Pharmaceuticals' Strategic Moves - Shanghai Pharmaceuticals has been optimizing its assets, having invested nearly 1 billion yuan to gain further control of Huang Pharmaceutical last year, acquiring several traditional Chinese medicine products [2] - The company has also made acquisitions of multiple DTP pharmacy enterprises through its subsidiary, Shanghai Pharmaceuticals Cloud Health platform [2] - In terms of R&D, Shanghai Pharmaceuticals has increased its investment, with a total of 1.729 billion yuan in R&D for the first three quarters of 2025, and currently has 57 new drug pipelines, including 45 innovative drugs [2] Group 4: Financial Performance of Shanghai Pharmaceuticals - For the first three quarters of 2025, Shanghai Pharmaceuticals reported revenues of 215.072 billion yuan, a year-on-year increase of 2.60%, and a net profit attributable to shareholders of 5.147 billion yuan, up 26.96% [2] - However, the net profit after deducting losses was 3.979 billion yuan, reflecting a year-on-year decrease of 1.85% [2]